Skip to main content
Clinical Trials/NL-OMON32415
NL-OMON32415
Recruiting
Not Applicable

The predictive value of FDG-PET-CT early during (chemo-)radiotherapy for local control of advanced stage head and neck cancer - PETPRED study

Vrije Universiteit Medisch Centrum0 sites20 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Vrije Universiteit Medisch Centrum
Enrollment
20
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • patients with resectable advanced (stage III and IV) HNSCC scheduled for primary non\-surgical treatment (radiotherapy with or without chemotherapy) with curative intent.

Exclusion Criteria

  • technically inoperable tumor

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
TILITY OF PREOPERATIVE FDG-PET/CT SCANNING PRIOR TO PRIMARY CHEMORADIATIONTHERAPY TO DETECT RETROPERITONEAL LYMPH NODE METASTASIS IN PATIENTS WITH LOCOREGIONALLY ADVANCED CARCINOMA OF THE CERVIX (IB2, IIA >=;4 CM, IIB-IVA) OR ENDOMETRIUM (GRADE 3 ENDOMETRIOID ENDOMETRIAL CARCINOMA; SEROUS PAPILLARY CARCINOMA, CLEAR CELL CARCINOMA, OR CARCINOSARCOMA (ANY GRADE); AND GRADE 1 OR 2 ENDOMETRIOID ENDOMETRIAL CARCINOMA WITH CERVICAL STROMAL INVOLVEMENT OVERT IN CLINICAL EXAMINATION OR CONFIRMED BY ENDOCERVICAL CURETTAGE)PATIENTS WITH LOCOREGIONALLY ADVANCED CARCINOMA OF THE CERVIX (IB2, IIA &gt=4 CM, IIB-IVA) OR ENDOMETRIUM (GRADE 3 ENDOMETRIOID ENDOMETRIAL CARCINOMASEROUS PAPILLARY CARCINOMA, CLEAR CELL CARCINOMA, OR CARCINOSARCOMA (ANY GRADE)AND GRADE 1 OR 2 ENDOMETRIOID ENDOMETRIAL CARCINOMA WITH CERVICAL STROMAL INVOLVEMENT OVERT IN CLINICAL EXAMINATION OR CONFIRMED BY ENDOCERVICAL CURETTAGE)
JPRN-UMIN000006787ational Cancer Institute380
Recruiting
Not Applicable
Response prediction of third-line cetuximab-based therapy for patients with metastatic colorectal cancer using Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT)Metastatic colorectal cancer receiving third-line therapy with cetuximabCancer - Bowel - Back passage (rectum) or large bowel (colon)
ACTRN12612000052831Chang Gung Memorial Hospital30
Completed
Not Applicable
Accuracy of FDG-PET and spiral CT for the early prediction of non-response to preoperative chemoradiotherapy in patients with oesophageal cancerOesophageal cancerCancerMalignant neoplasm of oesophagus
ISRCTN45750457Academic Medical Centre (AMC) (Netherlands)150
Recruiting
Not Applicable
Accuracy of FDG-PET and spiral CT for the early prediction of non-response to preoperative chemoradiotherapy in patients with esophageal cancer.Esophageal cancer
NL-OMON26500Academic Medical Center150
Completed
Not Applicable
sefulness of FDG-PET/CT examination as prediction of effect of immune checkpoint inhibitors in patients with non-small cell lung cancer : a pilot studyadvanced and recurrent non-small cell lung cancer
JPRN-UMIN000031095Kansai Medical University30